Cancer immune activity measured by interferon (IFN)-γ response, fractional change, and tumor-infiltrating lymphocytes (TIL) fraction were all significantly lower in the NR2F1-high tumors in TCGA (Figure 5A). This evidence concerns the gene NR2F1 and neoplasm.